Logo image of IPH.PA

INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

EPA:IPH - Euronext Paris - Matif - FR0010331421 - Common Stock - Currency: EUR

1.872  -0.01 (-0.32%)

Fundamental Rating

2

IPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. IPH has a bad profitability rating. Also its financial health evaluation is rather negative. IPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPH had negative earnings in the past year.
IPH had a negative operating cash flow in the past year.
IPH had negative earnings in each of the past 5 years.
IPH had negative operating cash flow in 4 of the past 5 years.
IPH.PA Yearly Net Income VS EBIT VS OCF VS FCFIPH.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of -22.48%, IPH perfoms like the industry average, outperforming 56.76% of the companies in the same industry.
The Return On Equity of IPH (-118.25%) is worse than 60.81% of its industry peers.
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROIC N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
IPH.PA Yearly ROA, ROE, ROICIPH.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

IPH's Gross Margin of 88.00% is amongst the best of the industry. IPH outperforms 85.14% of its industry peers.
IPH's Gross Margin has been stable in the last couple of years.
IPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
IPH.PA Yearly Profit, Operating, Gross MarginsIPH.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPH has been increased compared to 1 year ago.
The number of shares outstanding for IPH has been increased compared to 5 years ago.
IPH has a better debt/assets ratio than last year.
IPH.PA Yearly Shares OutstandingIPH.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
IPH.PA Yearly Total Debt VS Total AssetsIPH.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

IPH has an Altman-Z score of -2.67. This is a bad value and indicates that IPH is not financially healthy and even has some risk of bankruptcy.
IPH has a worse Altman-Z score (-2.67) than 62.16% of its industry peers.
IPH has a Debt/Equity ratio of 2.73. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IPH (2.73) is worse than 67.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Altman-Z -2.67
ROIC/WACCN/A
WACC7.58%
IPH.PA Yearly LT Debt VS Equity VS FCFIPH.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

IPH has a Current Ratio of 2.92. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.92, IPH is doing good in the industry, outperforming 64.86% of the companies in the same industry.
A Quick Ratio of 2.92 indicates that IPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.92, IPH is in the better half of the industry, outperforming 66.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
IPH.PA Yearly Current Assets VS Current LiabilitesIPH.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.49%, which is quite impressive.
IPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.07%.
IPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.27% yearly.
EPS 1Y (TTM)46.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1530.84%
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%

3.2 Future

The Earnings Per Share is expected to grow by 41.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, IPH will show a very strong growth in Revenue. The Revenue will grow by 25.26% on average per year.
EPS Next Y23.22%
EPS Next 2Y32.42%
EPS Next 3Y41.6%
EPS Next 5YN/A
Revenue Next Year-23.96%
Revenue Next 2Y21.26%
Revenue Next 3Y38.8%
Revenue Next 5Y25.26%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPH.PA Price Earnings VS Forward Price EarningsIPH.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPH.PA Per share dataIPH.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

IPH's earnings are expected to grow with 41.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.42%
EPS Next 3Y41.6%

More info and screens

0

5. Dividend

5.1 Amount

IPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA

EPA:IPH (3/14/2025, 7:00:00 PM)

1.872

-0.01 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners9.86%
Inst Owner ChangeN/A
Ins Owners2.39%
Ins Owner ChangeN/A
Market Cap156.90M
Analysts76
Price Target5.27 (181.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.68%
PT rev (3m)2.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.52%
EPS NY rev (3m)-7.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-7.24%
Revenue NY rev (3m)-6.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.31
P/FCF N/A
P/OCF N/A
P/B 5.45
P/tB 5.47
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.3
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.48%
ROE -118.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88%
FCFM N/A
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 2.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.84%
Cap/Sales 9.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -2.67
F-Score2
WACC7.58%
ROIC/WACCN/A
Cap/Depr(3y)25.89%
Cap/Depr(5y)98.67%
Cap/Sales(3y)5.93%
Cap/Sales(5y)26.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1530.84%
EPS Next Y23.22%
EPS Next 2Y32.42%
EPS Next 3Y41.6%
EPS Next 5YN/A
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%
Revenue Next Year-23.96%
Revenue Next 2Y21.26%
Revenue Next 3Y38.8%
Revenue Next 5Y25.26%
EBIT growth 1Y-52.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.08%
EBIT Next 3Y46.8%
EBIT Next 5YN/A
FCF growth 1Y25.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.75%
OCF growth 3YN/A
OCF growth 5YN/A